Skip to content
Review Open access

Structural basis of anti-MHC-I antibody blocking of inhibitory NK cell receptors in tumor immunity 2299676

Jul 2026 · Journal of Immunology · Vol 215 · 0 citations

TL;DR

The structure of a broadly reactive anti-human MHC-I mAb, B1.23.2, is determined and a mechanism of anti-MHC-I mAb blocking NK cell inhibitory receptors, which is distinct from other checkpoint mAb mechanisms is proposed.

Abstract

Anti-MHC-I mAbs in human and murine systems can stimulate immune responses to tumors and infections by competitively blocking inhibitory signals delivered by MHC-I-specific inhibitory receptors of several inflammatory cell types (Panda, A.K. et al. J Immunol, 2020). Previous work showed that anti-MHC-I mAbs could activate immune responses by blocking the interactions of HLA with inhibitory receptors like leukocyte immunoglobulin-like receptors LILR (Panda, A.K. et al. Cancer Immunol. Res., 2025). Here, we determined the structure of a broadly reactive anti-human MHC-I mAb, B1.23.2, in complex with the MHC-I molecule HLA-B*44:05 by both X-ray crystallography and cryo-electron microscopy (cryo-EM) (Jiang J. et al. Commun. Biol. 2025, in review) The determined structure revealed that B1.23.2 binds to a conserved region on the MHC-I molecule that overlaps with the binding sites for killer immunoglobulin-like receptors (KIRs), indicating the binding competition between anti-MHC-I mAb and KIRs. These studies prompted experiments evaluating B1.23.2 treatment in the human KLM-1 pancreatic cancer model using humanized (NSG-IL15) mice, providing evidence of tumor growth suppression by these anti-MHC-I mAbs. We proposed a mechanism of anti-MHC-I mAb blocking NK cell inhibitory receptors, which is distinct from other checkpoint mAb mechanisms. These results provide new insights into the structural basis of how anti-MHC-I antibodies can be used in cancer immunotherapy by specifically targeting inhibitory receptor interactions. This work was supported by the Division of Intramural Research, NIAID, NIH. Classical and Non-Classical Antigen Presenting Cells (APC)

Read PDF

Similar papers

Review Open access Aug 2026

Emerging therapeutic opportunities targeting nonclassical MHC-I molecules.

The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.

Yan-Ruide Li, Yu-Ning Chen, Li-Li Yang · 0 citations
Open access Sep 2026

Cryo-EM and X-ray structures of an anti-MHC-I monoclonal antibody/H2-Kb complex reveal the basis of conformational dependence and allelic specificity

Monoclonal antibodies (mAbs) directed against MHC class I molecules (MHC-I) have been invaluable for a host of functions including tissue typing for transplantation, exploration of immune activation, and probing molecular structure and dynamics. We previously studied a set of murine mAbs directed against MHC-I to chara...

Jian-Sheng Jiang, K. Natarajan, Reanne R. Towler et al. · 0 citations
Open access Aug 2026

Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR β chain-directed selective dual T-cell activator

Administration of anti-PD-1 with a bifunctional fusion molecule, anti-TCRβ-IL-2 followed by anti-PD-1 greatly enhanced anti-tumor efficacy leading to tumor cures and long-term protection in several murine models resistant to ICI.

Shantel Angstadt, Lucas A. Horn, Kristen Fousek et al. · 0 citations
Open access Aug 2026

Leukocyte Immunoglobulin-Like Receptor B1 and its Interactions with Human Leukocyte Antigens

Interactions between Human Leukocyte Antigen (HLA) molecules and their cognate immunoreceptors are essential for regulating innate and adaptive immune cell functions. Leukocyte Immunoglobulin-like Receptors (LILRs) are key regulators of HLA-mediated immune responses, owing to their broad expression across immune cell p...

Geoff Zhang, Jia Q Truong, Lucy C. Sullivan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.